37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To determine efficacy and safety of intravitreal aflibercept in patients with neovascular age-related macular degeneration (AMD) during a second year of variable dosing after a first-year fixed-dosing period.

          Related collections

          Author and article information

          Journal
          Ophthalmology
          Ophthalmology
          Elsevier BV
          1549-4713
          0161-6420
          Jan 2014
          : 121
          : 1
          Affiliations
          [1 ] Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
          [2 ] Department of Ophthalmology, Cole Eye Institute, Cleveland, Ohio.
          [3 ] Department of Ophthalmology, Centre Hospitalier Universitaire de Bordeaux, Université Bordeaux 2, Bordeaux, France.
          [4 ] Retina Consultants of Houston, Houston, Texas.
          [5 ] Oxford Eye Hospital, University of Oxford, Oxford, United Kingdom.
          [6 ] Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
          [7 ] Wills Eye Hospital and Mid Atlantic Retina, Philadelphia, Pennsylvania.
          [8 ] Department of Ophthalmology, Nagoya City University, Nagoya, Japan.
          [9 ] Department of Ophthalmology, Duke University, Durham, North Carolina.
          [10 ] Vitreous-Retina-Macula Consultants of New York, New York, New York.
          [11 ] Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
          [12 ] Bayer HealthCare, Berlin, Germany.
          [13 ] Bayer HealthCare, Berlin, Germany; Universitatsklinikum Hamburg-Eppendorf, Klinik und Poliklinik fur Augenheilkunde, Hamburg, Germany.
          [14 ] Bayer HealthCare, Berlin, Germany; Department of Neurology, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
          [15 ] Ophthalmic Consultants of Boston and Tufts University School of Medicine, Boston, Massachusetts. Electronic address: jsheier@eyeboston.com.
          Article
          S0161-6420(13)00729-X
          10.1016/j.ophtha.2013.08.011
          24084500
          7bd8f966-ace6-437b-90ef-ab6ddecda3f8
          Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article